Breakthrough Science for Better Health

Passionately committed to bettering the lives of patients with kidney and cardiovascular diseases.
Learn About Us

Patients

We are committed to scientific and clinical integrity with a passionate pursuit of medical innovation to deliver the highest-quality therapeutics to better the lives of patients with kidney and cardiovascular diseases.

LEARN MORE

Programs

Our pipeline of gut-restricted therapies is concentrated on providing better medicines to patients in need.

LEARN MORE

Investors

We are executing a strategic plan focused on bringing important medicines to patients in need, while generating value for our shareholders.

LEARN MORE

THE FACTS

740,000 ESRD patients with hyperphosphatemia in major developed countries
>500K U.S. Dialysis Patients
~95% of CKD patients on dialysis need phosphate control
~2 Million people in U.S. with CKD and/or heart failure have hyperkalemia
Impact

Making Better Medicine For Patients In Need

We are advancing our lead product, tenapanor, for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

Learn More About Our Tenapanor Programs
May
20
2020
05.20.2020
Ardelyx CEO Mike Raab Named Top Healthcare CEO by The Technology Healthcare Report

Mike Raab, president and CEO of Ardelyx named to list of top CEOS by The Technology Healthcare Report in their “The Top 50 Healthcare Technology CEOs of 2020” list.
May
18
2020
05.18.2020
Ardelyx Strengthens Management Team with Appointment of Susan Rodriguez as Chief Commercial Officer

Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced the appointment of Susan…
May
07
2020
05.07.2020
Ardelyx Reports First Quarter 2020 Financial Results and Recent Business Highlights

Ardelyx, Inc. (Nasdaq:ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today reported business highlights and financial results…
Mar
06
2019
03.06.2019
Ardelyx Appoints Onaiza Cadoret-Manier to its Board of Directors

Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that Onaiza Cadoret-Manier, an industry veteran…

- Kelli, HR

Make An Impact With Us

PIPELINE

PROGRAM
INDICATION
RESEARCH
PHASE 1
PHASE 2
PHASE 3
APPROVED
Cardiorenal Programs
Tenapanor
ESRD Hyperphosphatemia
(NHE3 Inhibitor)
RDX011
Cardiorenal Indications
(NHE3 Inhibitor)
RDX013
Hyperkalemia
(Potassium Secretagogue)
Gastrointestinal Programs
Tenapanor
IBS-C
(NHE3 Inhibitor)
RDX011
GI Indications
(NHE3 Inhibitor)
Learn More About Our Programs